Enhanced MHC class I and costimulatory molecules on B16F10 cells by Ganoderma lucidum polysaccharides. 2012

Li-Xin Sun, and Zhi-Bin Lin, and Xin-Suo Duan, and Jie Lu, and Zhi-Hua Ge, and Xue-Fei Li, and Xue-Jun Li, and Min Li, and En-Hong Xing, and You-Xin Song, and Jing Jia, and Wei-Dong Li
Department of Pharmacology, Peking University Health Science Center, School of Basic Medical Sciences, Beijing, China.

OBJECTIVE It is obvious that malignant cells evade from immune system in patients with manifest malignancy. Deficient major histocompatibility complex (MHC) class I and costimulatory molecules on malignant cells partially consist of evasion strategy since antigen bond MHC and costimulatory molecules provide two signals necessary for T cell activation. Therefore, enhancement of MHC-I and costimulatory molecules may favor restraint of the evasion. For this purpose, Ganoderma lucidum Polysaccharides (Gl-PS) was used on B16F10 melanoma cells in this study. METHODS Immunocytochemistry and flowcytometry were used to determine the H-2K(b) and H-2D(b) (two prominent MHC class I molecules in C57BL mouse) as well as B7-1 and B7-2 (two prominent costimulatory molecules) expression on B16F10 cells after incubation with Gl-PS, while messenger ribonucleic acid (mRNA) of these molecules was detected by reverse transcription polymerase chain reaction (RT-PCR). RESULTS The H-2K(b) and H-2D(b), and B7-1 and B7-2 on B16F10 cells and mRNAs of these molecules were enhanced by Gl-PS, and more efficient antitumor cytotoxicity was induced by the Gl-PS treated cells. CONCLUSIONS The MHC class I molecules and costimulatory molecules may be enhanced by Gl-PS, and more efficient immune cell mediated cytotoxicity against these B16F10 cells may be induced, which may favor cancer therapy.

UI MeSH Term Description Entries
D008546 Melanoma, Experimental Experimentally induced tumor that produces MELANIN in animals to provide a model for studying human MELANOMA. B16 Melanoma,Melanoma, B16,Melanoma, Cloudman S91,Melanoma, Harding-Passey,Experimental Melanoma,Experimental Melanomas,Harding Passey Melanoma,Melanomas, Experimental,B16 Melanomas,Cloudman S91 Melanoma,Harding-Passey Melanoma,Melanoma, Harding Passey,Melanomas, B16,S91 Melanoma, Cloudman
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D011134 Polysaccharides Long chain polymeric CARBOHYDRATES composed of MONOSACCHARIDES linked by glycosidic bonds. Glycan,Glycans,Polysaccharide
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D005805 Genes, MHC Class I Genetic loci in the vertebrate major histocompatibility complex which encode polymorphic characteristics not related to immune responsiveness or complement activity, e.g., B loci (chicken), DLA (dog), GPLA (guinea pig), H-2 (mouse), RT-1 (rat), HLA-A, -B, and -C class I genes of man. Class I Genes,Genes, Class I,Genes, H-2 Class I,Genes, HLA Class I,MHC Class I Genes,H-2 Class I Genes,HLA Class I Genes,Class I Gene,Gene, Class I,Genes, H 2 Class I,H 2 Class I Genes
D006183 H-2 Antigens The major group of transplantation antigens in the mouse. H2 Antigens,Antigens, H-2,Antigens, H2,H 2 Antigens
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000972 Antineoplastic Agents, Phytogenic Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity. Antineoplastics, Botanical,Antineoplastics, Phytogenic,Agents, Phytogenic Antineoplastic,Botanical Antineoplastics,Phytogenic Antineoplastic Agents,Phytogenic Antineoplastics
D015972 Gene Expression Regulation, Neoplastic Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue. Neoplastic Gene Expression Regulation,Regulation of Gene Expression, Neoplastic,Regulation, Gene Expression, Neoplastic
D049109 Cell Proliferation All of the processes involved in increasing CELL NUMBER including CELL DIVISION. Cell Growth in Number,Cellular Proliferation,Cell Multiplication,Cell Number Growth,Growth, Cell Number,Multiplication, Cell,Number Growth, Cell,Proliferation, Cell,Proliferation, Cellular

Related Publications

Li-Xin Sun, and Zhi-Bin Lin, and Xin-Suo Duan, and Jie Lu, and Zhi-Hua Ge, and Xue-Fei Li, and Xue-Jun Li, and Min Li, and En-Hong Xing, and You-Xin Song, and Jing Jia, and Wei-Dong Li
October 2002, Immunology letters,
Li-Xin Sun, and Zhi-Bin Lin, and Xin-Suo Duan, and Jie Lu, and Zhi-Hua Ge, and Xue-Fei Li, and Xue-Jun Li, and Min Li, and En-Hong Xing, and You-Xin Song, and Jing Jia, and Wei-Dong Li
November 2016, Trends in immunology,
Li-Xin Sun, and Zhi-Bin Lin, and Xin-Suo Duan, and Jie Lu, and Zhi-Hua Ge, and Xue-Fei Li, and Xue-Jun Li, and Min Li, and En-Hong Xing, and You-Xin Song, and Jing Jia, and Wei-Dong Li
February 2004, Acta pharmacologica Sinica,
Li-Xin Sun, and Zhi-Bin Lin, and Xin-Suo Duan, and Jie Lu, and Zhi-Hua Ge, and Xue-Fei Li, and Xue-Jun Li, and Min Li, and En-Hong Xing, and You-Xin Song, and Jing Jia, and Wei-Dong Li
January 2017, Oncoimmunology,
Li-Xin Sun, and Zhi-Bin Lin, and Xin-Suo Duan, and Jie Lu, and Zhi-Hua Ge, and Xue-Fei Li, and Xue-Jun Li, and Min Li, and En-Hong Xing, and You-Xin Song, and Jing Jia, and Wei-Dong Li
April 1991, Nature,
Li-Xin Sun, and Zhi-Bin Lin, and Xin-Suo Duan, and Jie Lu, and Zhi-Hua Ge, and Xue-Fei Li, and Xue-Jun Li, and Min Li, and En-Hong Xing, and You-Xin Song, and Jing Jia, and Wei-Dong Li
July 1996, Trends in cell biology,
Li-Xin Sun, and Zhi-Bin Lin, and Xin-Suo Duan, and Jie Lu, and Zhi-Hua Ge, and Xue-Fei Li, and Xue-Jun Li, and Min Li, and En-Hong Xing, and You-Xin Song, and Jing Jia, and Wei-Dong Li
February 1996, Cellular immunology,
Li-Xin Sun, and Zhi-Bin Lin, and Xin-Suo Duan, and Jie Lu, and Zhi-Hua Ge, and Xue-Fei Li, and Xue-Jun Li, and Min Li, and En-Hong Xing, and You-Xin Song, and Jing Jia, and Wei-Dong Li
January 1997, Biopolymers,
Li-Xin Sun, and Zhi-Bin Lin, and Xin-Suo Duan, and Jie Lu, and Zhi-Hua Ge, and Xue-Fei Li, and Xue-Jun Li, and Min Li, and En-Hong Xing, and You-Xin Song, and Jing Jia, and Wei-Dong Li
October 2004, Biochemical and biophysical research communications,
Li-Xin Sun, and Zhi-Bin Lin, and Xin-Suo Duan, and Jie Lu, and Zhi-Hua Ge, and Xue-Fei Li, and Xue-Jun Li, and Min Li, and En-Hong Xing, and You-Xin Song, and Jing Jia, and Wei-Dong Li
January 2012, Frontiers in pharmacology,
Copied contents to your clipboard!